Center-Authored Papers

Filters: Author is Thorpe, Jason D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Yeasts
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Tumor Markers, Biological
Time Factors
Specimen Processing Core Facility
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Shared Resources
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Sensitivity and Specificity
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
ROC Curve
Risk Factors
Risk Assessment
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Reproducibility of Results
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Recombinant Fusion Proteins
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Receptors, Tumor Necrosis Factor, Member 6b
Public Health Sciences Division
Karlan BY, Thorpe JD, Watabayashi K, Drescher CW, Palomares MR, Daly M, Paley PJ, Hillard PJ, Andersen MR, Anderson GL et al..  2014.  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract